Clinicopathological significance of SIRT1 expression in colorectal cancer: A systematic review and meta analysis

International Journal of Surgery

Volumn 26, Issue , 2016, Pages 32-37

  Zu, Guo ^a   Ji, Anlong ^a   Zhou, Tingting ^a   Che, Ningwei ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Clinicopathological characteristics; Colorectal cancer; Prognosis; SIRT1

Indexed keywords

BIOLOGICAL MARKER; SIRTUIN 1; SIRT1 PROTEIN, HUMAN; TUMOR MARKER;

CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CLINICAL FEATURE; COLORECTAL CANCER; HUMAN; LYMPH NODE METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SYSTEMATIC REVIEW; TUMOR INVASION; COLORECTAL TUMOR; META ANALYSIS; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS;

BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; NEOPLASM INVASIVENESS; PROGNOSIS; SIRTUIN 1; SURVIVAL ANALYSIS;

EID: 84957818711     PISSN: 17439191     EISSN: 17439159     Source Type: Journal    
DOI: 10.1016/j.ijsu.2016.01.002     Document Type: Review

References (30)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010 Dec 15, 127(12):2893-2917.
2. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011 Mar-Apr, 61(2):69-90.
3. Siegel R., Desantis C., Jemal A. Colorectal cancer statistics. CA Cancer J. Clin. 2014 Mar-Apr, 64(2):104-117.
4. Go P.H., Klaassen Z., Meadows M.C., Chamberlain R.S. Gastrointestinal cancer and brain metastasis: a rare and ominous sign. Cancer 2011 Aug 15, 117(16):3630-3640.
5. Li Y., Yokota T., Gama V., Yoshida T., Gomez J.A., Ishikawa K., Sasaguri H., Cohen H.Y., Sinclair D.A., Mizusawa H., Matsuyama S. Bax-inhibiting peptide protects cells from polyglutamine toxicity caused by Ku70 acetylation. Cell Death Differ. 2007 Dec, 14(12):2058-2067.
6. Langley E., Pearson M., Faretta M., Bauer U.M., Frye R.A., Minucci S., Pelicci P.G., Kouzarides T. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 2002 May 15, 21(10):2383-2396.
7. Han M.K., Song E.K., Guo Y., Ou X., Mantel C., Broxmeyer H.E. SIRT1 regulates apoptosis and nanog expression in mouse embryonic stem cells by controlling p53 subcellular localization. Cell Stem Cell. 2008 Mar 6, 2(3):241-251.
8. Brunet A., Sweeney L.B., Sturgill J.F., Chua K.F., Greer P.L., Lin Y., Tran H., Ross S.E., Mostoslavsky R., Cohen H.Y., Hu L.S., Cheng H.L., Jedrychowski M.P., Gygi S.P., Sinclair D.A., Alt F.W., Greenberg M.E. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004 Mar 26, 303(5666):2011-2015.
9. Liu T., Liu P.Y., Marshall G.M. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res. 2009 Mar 1, 69(5):1702-1705.
10. Huffman D.M., Grizzle W.E., Bamman M.M., Kim J.S., Eltoum I.A., Elgavish A., Nagy T.R. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 2007 Jul 15, 67(14):6612-6618.
11. Elangovan S., Ramachandran S., Venkatesan N., Ananth S., Gnana-Prakasam J.P., Martin P.M., Browning D.D., Schoenlein P.V., Prasad P.D., Ganapathy V., Thangaraju M. SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor α in breast cancer. Cancer Res. 2011 Nov 1, 71(21):6654-6664.
12. Song N.Y., Surh Y.J. Janus-faced role of SIRT1 in tumorigenesis. Ann. N. Y. Acad. Sci. 2012 Oct, 1271:10-19.
13. Cohen H.Y., Miller C., Bitterman K.J., Wall N.R., Hekking B., Kessler B., Howitz K.T., Gorospe M., de Cabo R., Sinclair D.A. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004 Jul 16, 305(5682):390-392.
14. Firestein R., Blander G., Michan S., Oberdoerffer P., Ogino S., Campbell J., Bhimavarapu A., Luikenhuis S., de Cabo R., Fuchs C., Hahn W.C., Guarente L.P., Sinclair D.A. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 2008 Apr 16, 3(4):e2020.
15. Wang R.H., Zheng Y., Kim H.S., Xu X., Cao L., Luhasen T., Lee M.H., Xiao C., Vassilopoulos A., Chen W., Gardner K., Man Y.G., Hung M.C., Finkel T., Deng C.X. Interplay among BRCA1, SIRT1, and survivin during BRCA1-associated tumorigenesis. Mol. Cell 2008 Oct 10, 32(1):11-20.
16. Jung W., Hong K.D., Jung W.Y., Lee E., Shin B.K., Kim H.K., Kim A., Kim B.H. SIRT1 expression is associated with good prognosis in colorectal cancer. Korean J. Pathol. 2013 Aug, 47(4):332-339.
17. Jang S.H., Min K.W., Paik S.S., Jang K.S. Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma. J. Clin. Pathol. 2012 Aug, 65(8):735-739.
18. Chen X., Sun K., Jiao S., Cai N., Zhao X., Zou H., Xie Y., Wang Z., Zhong M., Wei L. High levels of SIRT1 expression enhance tumorigenesis and associate with a poor prognosis of colorectal carcinoma patients. Sci. Rep. 2014 Dec 15, 4:7481.
19. Jiang K., Lyu L., Shen Z., Zhang J., Zhang H., Dong J., Yan Y., Liu F., Wang S. Overexpression of SIRT1 is a poor prognostic factor for advanced colorectal cancer. Chin. Med. J. Engl. 2014, 127(11):2021-2024.
20. Zhao M., Liang F., Zhang B., Yan W., Zhang J. The impact of osteopontin on prognosis and clinicopathology of colorectal cancer patients: a systematic meta-analysis. Sci. Rep. 2015 Aug 3, 5:12713.
21. Zhang X., Chen S., Cheng M., Cao F., Cheng Y. The expression and correlation of SIRT1 and phospho-SIRT1 in colorectal cancer. Int. J. Clin. Exp. Med. 2015 Jan 15, 8(1):809-817.
22. Nosho K., Shima K., Irahara N., Kure S., Firestein R., Baba Y., Toyoda S., Chen L., Hazra A., Giovannucci E.L., Fuchs C.S., Ogino S. SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod. Pathol. 2009 Jul, 22(7):922-932.
23. Ma J.J., Guo S.Q., Zhang Y.L., Li Z.H., Zhang J.K., Zhou B.J., Zhu C.Y. Significance of silent information regulator type 1 and multifrug resistance gene in colorectal cancer. Clin. Focus 2012 December, 27(24):2145-2148.
24. Bosch-Presegué L., Vaquero A. The dual role of sirtuins in cancer. Genes Cancer 2011 Jun, 2(6):648-662.
25. Kuzmichev A., Margueron R., Vaquero A., Preissner T.S., Scher M., Kirmizis A., Ouyang X., Brockdorff N., Abate-Shen C., Farnham P., Reinberg D. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc. Natl. Acad. Sci. U. S. A. 2005 Feb 8, 102(6):1859-1864.
26. Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I.R., Lu L., Irvin D., Black K.L., Yu J.S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 2006 Dec 2, 5:67.
27. Hida Y., Kubo Y., Murao K., Arase S. Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch. Dermatol. Res. 2007 May, 299(2):103-106.
28. Elangovan S., Ramachandran S., Venkatesan N., Ananth S., Gnana-Prakasam J.P., Martin P.M., Browning D.D., Schoenlein P.V., Prasad P.D., Ganapathy V., Thangaraju M. SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor α in breast cancer. Cancer Res. 2011 Nov 1, 71(21):6654-6664.
29. Pruitt K., Zinn R.L., Ohm J.E., McGarvey K.M., Kang S.H., Watkins D.N., Herman J.G., Baylin S.B. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet. 2006 Mar, 2(3):e40.
30. Wang R.H., Sengupta K., Li C., Kim H.S., Cao L., Xiao C., Kim S., Xu X., Zheng Y., Chilton B., Jia R., Zheng Z.M., Appella E., Wang X.W., Ried T., Deng C.X. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell. 2008 Oct 7, 14(4):312-323.